◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksC › CBLL

CeriBell, Inc (CBLL) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-18

CeriBell, Inc (CBLL) operates in the MEDICAL DEVICES industry and is headquartered in Sunnyvale, United States with about 327 employees. Its market capitalization is roughly $935 million. In the fiscal year ended 2025-12-31, CBLL reported $89M in revenue and ($53M) in net income.

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.

Interactive charts & full statements → Open the CBLL valuation workbench →

CBLL Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-31
Total Revenue$102M$89M$65M$45M$26M
Gross Profit$91M$78M$57M$38M$21M
Gross Margin %88.9%87.9%86.7%84.4%82.9%
Operating Income (EBIT)($70M)($58M)($40M)($30M)($36M)
Operating Margin %-68.6%-65.6%-60.7%-66.4%-139.0%
Net Income($66M)($53M)($40M)($29M)($37M)
Net Margin %-64.7%-60.0%-61.8%-65.1%-143.4%
EBITDA($63M)($50M)($37M)($27M)($35M)
Earnings Per Share (EPS)$-1.76$-1.46$-1.13$-1.26$-1.59
Shares Outstanding (M)38M37M36M23M23M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBLL Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$28M$26M$25M$23M$21M$20M$19M$17M
Gross Profit$26M$23M$22M$20M$19M$18M$16M$15M
Gross Margin %92.3%87.3%87.3%88.3%88.1%87.9%87.6%87.3%
Operating Income (EBIT)($20M)($21M)($15M)($15M)($15M)($14M)($13M)($10M)
Operating Margin %-71.1%-78.3%-58.9%-64.8%-70.5%-69.3%-69.5%-57.8%
Net Income($19M)($20M)($14M)($13M)($14M)($13M)($13M)($10M)
Net Margin %-68.6%-74.5%-54.6%-59.6%-64.4%-62.4%-67.8%-60.6%
EBITDA($19M)($19M)($13M)($13M)($13M)($12M)($12M)($10M)
Earnings Per Share (EPS)$-0.51$-0.52$-0.36$-0.37$-0.38$-0.36$-0.40$-0.31
Shares Outstanding (M)38M38M37M37M36M36M31M34M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBLL Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-31
Cash from Operations (CFO)($54M)($41M)($35M)($29M)($32M)
Capital Expenditures (CapEx)$2M$1M$1M$1M$1M
Free Cash Flow (FCF)($56M)($42M)($36M)($30M)($33M)
FCF Margin %-55.2%-46.7%-55.6%-66.6%-125.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBLL Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($13M)($19M)($11M)($11M)($8M)($11M)($10M)($9M)
Capital Expenditures (CapEx)$1M$1M$0M$0M$0M$0M$0M$1M
Free Cash Flow (FCF)($14M)($20M)($11M)($11M)($8M)($12M)($10M)($9M)
FCF Margin %-49.1%-75.9%-44.2%-50.8%-35.9%-57.0%-55.8%-53.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CBLL Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-31
Total Assets$166M$196M$225M$59M$86M
Cash & Cash Equivalents$33M$40M$194M$34M$68M
Total Liabilities$38M$40M$34M$171M$173M
Total Debt (Short + Long-Term)$21M$21M$21M$13M$16M
Total Shareholders' Equity$128M$155M$191M($112M)($86M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CBLL viewer.

Other Companies in MEDICAL DEVICES

← CBLAll “C” companiesCBLS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.